Corona Remedies Limited is an India-focused branded pharmaceutical formulation company established in 2004, specializing in the development, manufacturing, and marketing of products across high-growth therapeutic areas. The company’s core focus includes women’s healthcare, cardio-diabeto, pain management, and urology.

The company has demonstrated strong domestic growth, significantly outpacing the Indian Pharmaceutical Market (IPM). A key driver of this success is a differentiated strategy focused on the “middle of the pyramid,” specifically targeting specialist doctors. This approach has led to an improved market position, elevating Corona Remedies to among the top 30 largest pharmaceutical companies in India.

The company operates with a robust, pan-India marketing and distribution network spanning 22 states, supported by a significant field force. Manufacturing is handled through two facilities located in Gujarat, ensuring a consistent supply for its diverse brand portfolio. Corona Remedies maintains a strong emphasis on chronic and sub-chronic therapies, which form the majority of its domestic sales.

For the year/period ended (Rs. in Cr.)

For year/ period ended ( in Cr.)

*Market cap @upper band

• Second fastest growing company in the top 30 Indian pharmaceutical companies by domestic sales from MAT June 2022 to MAT June 2025, well-positioned to seize opportunities in the Indian market.
• Demonstrated capabilities of building a diversified portfolio, including “engine” brands, in our targeted therapy areas.
• Pan-India sales network and marketing strategy focused on the “middle of the pyramid” target market.
• Quality and current Good Manufacturing Practices-focused manufacturing facilities, with strong research and development capabilities driving a portfolio of differentiated pharmaceutical products.
• Qualified, experienced and entrepreneurial management team supported by marquee investors.

The objects of the Offer are to achieve the benefits of listing the Equity Shares on the Stock Exchanges.

The Company expects that listing of the Equity Shares will enhance our visibility and brand and provide liquidity to its existing Shareholders.

Utilization of the Offer Proceeds will not receive any proceeds from the Offer & and general corporate purposes.

At the upper band of IPO Rs. 1062, the stock is valued at 35.15 P/E multiple. Hence, well-informed investors subscribe for medium to long term perspective.